keangkong
GLP-1 Specialist
- Member Since
- Sep 2, 2024
- Posts
- 1,888
- Likes Received
- 4,991
Not very well. Only that there are different people don't respond to GLP-1 drugs. And figuring out which reason applies may one day help turn those nonresponders into people who benefit from GLP-1 drugs.Can you explain this in lay person?
The article essentially says......when someone doesn’t respond well to GLP-1 receptor agonist therapy, it’s not just because “the drug failed” — it might be because their biology isn’t suited (for now) to that therapy, due to receptor issues, signalling issues, or lack of endogenous hormone release. They argue that this could make it important in recognizing which mechanism is at play can help choose a more appropriate therapy, rather than simply increasing dose or changing drug without any insight. Having said that...they also say that currently there is no simple, validated diagnostics in every day practice to say definitively which “type” a person is.Can you explain this in lay person?
impaired enteroendecrine cell dysfunction Bet you can't say that fast five timesThose who have secretory deficiencies which are due to impaired enteroendecrine cell dysfunction? That would seem to explain ( to me anyway ) why some complain of " pronounced GI symptoms at low doses"? I'm not one of 'em ( I'm at 6mg -5 days and have not had any of what I've heard others complain of...YET🤞 ) but they relate their having sulpher burps, diarrhea and other GI issues at extremely low doses making them question whether they should continue use as treatments for weight loss.
It also says that they're "excellent responders to exogenous incretin therapy". Were I one of these super or hyper responders ( whatever the hell label they're given ) I would think I'd be looking into incretin therapy. And like GLP-1s initial introduction it seems that the studies are around T2D.